Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $504.89 million. The enterprise value is $463.24 million.
Important Dates
The last earnings date was Thursday, October 24, 2024, before market open.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 517.00 million shares outstanding. The number of shares has decreased by -1.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 517.00M |
| Shares Change (YoY) | -1.41% |
| Shares Change (QoQ) | -24.96% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 656.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 5.78 |
| PB Ratio | n/a |
| P/TBV Ratio | 3.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 1,119.48 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.56.
| Current Ratio | 3.53 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 209.36 |
| Debt / FCF | n/a |
| Interest Coverage | -1.08 |
Financial Efficiency
Return on equity (ROE) is -8.18% and return on invested capital (ROIC) is -1.64%.
| Return on Equity (ROE) | -8.18% |
| Return on Assets (ROA) | -1.38% |
| Return on Capital (ROIC) | -1.64% |
| Revenue Per Employee | $748,024 |
| Profits Per Employee | -$46,657 |
| Employee Count | 382 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.52 |
Taxes
In the past 12 months, Pharming Group has paid $622,000 in taxes.
| Income Tax | 622,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.36% in the last 52 weeks. The beta is 0.81, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -35.36% |
| 50-Day Moving Average | 8.28 |
| 200-Day Moving Average | 9.06 |
| Relative Strength Index (RSI) | 39.41 |
| Average Volume (20 Days) | 6,752 |
Short Selling Information
| Short Interest | 9,618 |
| Short Previous Month | 9,065 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 1.32 |
Income Statement
In the last 12 months, Pharming Group had revenue of $285.75 million and -$17.82 million in losses. Loss per share was -$0.03.
| Revenue | 285.75M |
| Gross Profit | 255.44M |
| Operating Income | -9.52M |
| Pretax Income | -15.41M |
| Net Income | -17.82M |
| EBITDA | -3.06M |
| EBIT | -9.52M |
| Loss Per Share | -$0.03 |
Full Income StatementBalance Sheet
The company has $171.77 million in cash and $127.08 million in debt, giving a net cash position of $44.68 million or $0.09 per share.
| Cash & Cash Equivalents | 171.77M |
| Total Debt | 127.08M |
| Net Cash | 44.68M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 225.79M |
| Book Value Per Share | 0.44 |
| Working Capital | 202.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $451,000 and capital expenditures -$964,000, giving a free cash flow of -$513,000.
| Operating Cash Flow | 451,000 |
| Capital Expenditures | -964,000 |
| Free Cash Flow | -513,000 |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
Gross margin is 89.39%, with operating and profit margins of -3.33% and -6.24%.
| Gross Margin | 89.39% |
| Operating Margin | -3.33% |
| Pretax Margin | -6.02% |
| Profit Margin | -6.24% |
| EBITDA Margin | -1.07% |
| EBIT Margin | -3.33% |
| FCF Margin | -2.35% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.41% |
| Shareholder Yield | 1.41% |
| Earnings Yield | -3.53% |
| FCF Yield | -0.10% |
Analyst Forecast
The average price target for Pharming Group is $33.50, which is 344.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.50 |
| Price Target Difference | 344.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 12.01% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.32 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.32 |
| Piotroski F-Score | 5 |